TAKARATAKARA BIO INC.

TOPICS

Takara Bio to Present Clinical Data from Investigator-Initiated Trial in Canada of NY-ESO-1 siTCR™ Gene Therapy at ASCO2022

Click here for the detail > News Release (2022/06/01)

Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies

Click here for the detail > News Release (2021/11/09)

Clinical program for NY-ESO-1 siTCR™ gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine

Click here for the detail > News Release (2020/06/24)

Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV

Click here for the detail > News Release (2019/09/27)

Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1 siTCR™ Gene Therapy at ESMO 2019

Click here for the detail > News Release (2019/09/24)

Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1 siTCR™ Gene Therapy at ASCO 2019

Click here for the detail > News Release (2019/05/16)

Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan

Click here for the detail > News Release (2019/03/29)

Designation Description Change of NY-ESO-1 siTCR™ gene therapy product under "SAKIGAKE Designation System"

Click here for the detail > News Release (2019/02/15)

Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress

Click here for the detail > News Release (2019/01/16)

return to top